SciClone Appoints Hong Zhao as Chief Executive Officer, China Operations

SciClone Appoints Hong Zhao as Chief Executive Officer, China Operations 
FOSTER CITY, CA -- (Marketwire) -- 03/22/13 --  SciClone
Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the appointment
of Hong Zhao as Chief Executive Officer, China Operations. Mr. Zhao
is an accomplished, respected pharmaceutical industry executive with
more than 20 years of experience in leading the commercial
operations, market expansion and growth of multi-national companies
in China. 
"Hong Zhao is a skilled executive with proven ability to exceed
aggressive performance goals, deliver strong top and bottom-line
performance, manage and inspire effective sales organizations,
establish productive relationships with industry partners and
implement innovative and effective corporate strategies," said
Friedhelm Blobel, Ph.D., SciClone Chief Executive Officer.
"Throughout his career, he has demonstrated the ability to bring new
ways of thinking into his companies, implement effective sales force
management strategies, incentives and performance measures, align
organizations toward growth and leverage the full potential of
individuals and teams. SciClone's board of directors and management
team join me in welcoming Hong to our Company. We look forward to
working together to lead SciClone to its next level of performance in
China."  
"I believe that SciClone has significant potential to enhance its
stature and reputation as a growth-focused mid-size pharmaceutical
company with a high quality, differentiated marketed product
portfolio, led by ZADAXIN(R), one of the most respected brands among
patients and physicians in China," said Mr. Zhao. "I look forward to
working with Friedhelm and the talented SciClone team to build a
consistently top-performing commercial organization, strengthen our
focus on ensuring compliance and integrity throughout our operations
and continue to deliver value to all of our stakeholders."  
Mr. Zhao joins SciClone from Simcere Pharmaceutical Group, a leading
pharmaceutical company specializing in the development,
manufacturing, and marketing of branded and proprietary
pharmaceuticals in China, where he served as Executive Vice
President, responsible for all business operations, including leading
a sizeable sales team and managing multiple busin
ess units, and had
direct reporting responsibility for medical affairs, market access,
marketing and sales operations, training and personnel development.
Prior to Simcere, he held positions of increasing seniority at
Novartis China, from Regional Sales Manager, National Sales Director,
Vice President, Senior Vice President of Novartis Greater China and
General Manager of Novartis Shanghai. Mr. Zhao also served with Xi'an
Janssen Pharmaceutical, where he rose quickly from Medical
Representative to District Sales Manager. Earlier in his career he
served as a lecturer and tutor at Nanjing Medical College. Mr. Zhao
earned a Bachelor of Medicine degree from Nanjing Medical College and
an Executive Masters of Business Administration degree from China
European International Business School (CEIBS) in Shanghai. He is
fluent in Mandarin and in English. 
About SciClone  
SciClone Pharmaceuticals is a US-based, China-focused specialty
pharmaceutical company with a product portfolio of therapies for
oncology, infectious diseases and cardiovascular, urological,
respiratory, and central nervous system disorders. SciClone's
ZADAXIN(R) (thymalfasin) is approved in over 30 countries and may be
used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and
certain cancers, and as a vaccine adjuvant, according to the local
regulatory approvals. Besides ZADAXIN, SciClone markets about 14
mostly partnered products in China, including Depakine(R), the most
widely prescribed broad-spectrum anti-convulsant in China;
Tritace(R), an ACE inhibitor for the treatment of hypertension;
Stilnox(R), a leading hypnotic for the short-term treatment of
insomnia (marketed as Ambien(R) in the US); and Aggrastat(R), a
recently-launched interventional cardiology product. SciClone is also
pursuing the registration of several other therapeutic products in
China. SciClone is headquartered in Foster City, California. For
additional information, please visit www.sciclone.com.  
Forward-Looking Statements This press release contains
forward-looking statements regarding expected financial results and
expectations. Readers are urged to consider statements that include
the words "may," "will," "would," "could," "should," "might,"
"believes," "estimates," "projects," "potential," "expects," "plans,"
"anticipates," "intends," "continues," "forecast," "designed,"
"goal," "unaudited," "approximately" or the negative of those words
or other comparable words to be uncertain and forward-looking. These
statements are subject to risks and uncertainties that are difficult
to predict and actual outcomes may differ materially. These include
risks and uncertainties relating to; the course, cost and outcome of
regulatory matters; the Company's ability to execute on its goals in
China and on its objectives; the challenges presented by integrating
an acquired business into existing operations;; the dependence on
third-party license, promotion or distribution agreements including
the need to renew such agreements; operating an international
business; the clinical trial process, including the regulatory
approval and the process of initiating trials at, and enrolling
patients at, clinical sites; the effect of changes in its practices
and policies related to the Company's compliance programs and
SciClone's ability to attract and retain key personnel. SciClone
cannot predict the timing or outcome of the on-going SEC and DOJ
investigations, or of the level of its efforts required to cooperate
with those investigations, however the Company has incurred
substantial expenses in connection with the investigations and
related litigation and expects to incur substantial additional
expense, and the investigations could result in fines and further
changes in its internal control or other remediation measures that
could adversely affect its business. Please also refer to other risks
and uncertainties described in SciClone's filings with the SEC. All
forward-looking statements are based on information currently
available to SciClone and SciClone assumes no obligation to update
any such forward-looking statements. 
Ambien, Depakine, Stilnox and Tritace are registered trademarks of
Sanofi and/or its affiliates. 
Aggrastat is a registered trademark of Medicure International Inc. in
the United States, and Iroko Cardio LLC in numerous other countries. 
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals
design, the SciClone logo and ZADAXIN are registered trademarks of
SciClone Pharmaceuticals, Inc. in the United States and numerous
other countries. 
Corporate Contacts 
Gary Titus 
Chief Financial Office
650.358.3456 
gtitus@sciclone.com  
Jane Green 
Investors/Media
650.358.1447
jgreen@sciclone.com